By Sheri Kasprzak
Atlanta, Dec. 10 - Introgen Therapeutics Inc. said Friday it raised $7.8 million in a direct placement with European institutional investors.
The investors are the same ones who purchased about $15 million of a $16.4 million direct placement wrapped Dec. 8.
Introgen sold 975,000 shares at $8 each. The shares in the deal were issued under the company's shelf registration.
Mulier Capital was the placement agent in the transaction.
Introgen is an Austin, Texas-based developer of biopharmaceutical products to treat cancer and other diseases. The company plans to use the proceeds from the financing for working capital and general corporate purposes, including developing its anti-cancer product candidates.
| Issuer: | Introgen Therapeutics Inc.
|
| Issue: | Stock
|
| Amount: | $7.8 million
|
| Shares: | 975,000
|
| Price: | $8.00
|
| Warrants: | No
|
| Placement agent: | Mulier Capital
|
| Settlement date: | Dec. 10
|
| Stock price: | $7.70 at close Dec. 9
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
